Personalized mRNA Skin Cancer Vaccine Cuts Relapse Risk by 42 Percent
An experimental personalized messenger RNA cancer vaccine developed by Moderna and Merck cut the risk of melanoma recurrence or death by 42 percent when combined with the immunotherapy drug Keytruda, according to clinical trial data highlighted by CNBC Arabia. The vaccine, known as intismeran autogene, matches each patient’s specific tumor mutations to train the immune system to target and destroy cancer cells following surgical removal.
The phase 3 clinical trial evaluated the combination therapy in high-risk melanoma patients after complete surgical resection of their tumors. Data cited by Investing.com showed that 82.2 percent of patients who received the intismeran autogene and Keytruda combination remained cancer-free two years after surgery, compared to 70 percent of patients treated with Keytruda alone. This approach utilizes the same mRNA technology platform previously deployed for coronavirus vaccines, though applied here to encode customized neoantigens unique to an individual’s malignancy.
Market Disruption Follows Unintended Data Disclosure
Moderna shares fell by up to 25 percent during Thursday trading after partial clinical trial data leaked ahead of a scheduled presentation at the European Society for Medical Oncology conference, CNBC Arabia reported. Merck shares simultaneously dropped 1.5 percent during mid-session trading as the unauthorized publication of the phase 3 findings generated widespread market confusion, according to Investing.com. The early disclosure appeared briefly on a medical news website near midday before being removed, triggering a broader sell-off across healthcare equities.
Trading volatility pushed Merck shares from a daily high of $154.02 down to $144.07 during the session, according to Investing.com. The unplanned release intersected with a downgrade to a “strong sell” rating from Zacks Research the previous day, alongside approximately $30 million in insider stock sales over the preceding quarter. Financial analysts continue to watch these developments ahead of Merck’s upcoming quarterly earnings report scheduled for October 29, where consensus estimates project $17.29 billion in revenue.
American schoolteacher Gary Keblesh shared his personal experience participating in the clinical trial during a presentation in Boston reported by STAT News. Diagnosed with melanoma, Keblesh received the personalized intismeran autogene vaccine alongside Keytruda following surgical intervention. He experienced peripheral neuropathy during the treatment protocol, which temporarily affected his mobility and daily routine before gradually improving with medical support and family assistance.
Keblesh returned to the classroom approximately six years after his initial tumor removal, illustrating how patients manage advanced immunotherapy regimens. While his case highlights the potential of customized oncology treatments, medical experts emphasize that the therapy remains investigational and requires formal regulatory review before gaining broad commercial availability.
Broader Oncology Applications Across Tumor Types
Medical researchers are actively testing personalized mRNA cancer vaccines and similar methodologies against other challenging malignancies, including lung, kidney, and pancreatic cancers.
How Intismeran Autogene Is Manufactured and Tested
How is intismeran autogene manufactured for each individual patient?
The manufacturing process begins with genetic sequencing of the patient’s surgically removed tumor to identify specific mutations. Technicians then use mRNA technology to encode those unique neoantigens into a customized vaccine designed to train the patient’s immune system to attack remaining cancer cells.
What specific combination drug was tested alongside the personalized mRNA vaccine?
The trial paired intismeran autogene with Keytruda, an established immunotherapy drug developed by Merck. Keytruda blocks specific molecular pathways that tumors use to evade detection, allowing the vaccine-trained immune system to locate and destroy malignant cells.
When did the market disruption and stock decline occur for Moderna and Merck?
The sharp stock decline occurred on Thursday following an unauthorized leak of phase 3 clinical data on a medical news website ahead of the European Society for Medical Oncology conference. Moderna shares fell by as much as 25 percent, while Merck shares dropped 1.5 percent during the trading session.
Keep reading